同: ATI

WordNet

a monoclonal antibody (trade name Remicade) used to treat Crohns disease and rheumatoid arthritis; administered by infusion; use and dosage must be determined by a physician (同)Remicade
an anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF; it is given intravenously at one-month to three-month intervals; used in treatment of regional enteritis and rheumatoid arthritis (同)Remicade
make a light, metallic sound; go `ting
a light clear metallic sound as of a small bell (同)tinkle
cause to make a ting
having a toe or toes of a specified kind; often used in combination; "long-toed; "five-toed"
alone and on your own; "dont just sit there on your tod"
a unit of weight for wool equal to about 28 pounds

PrepTutorEJDIC

《方向》(1)(到着の意を含めて)…『へ』,に,まで / 《状況の変化》…[のほう]へ;…に[なるまで],その結果…になる / 《適用範囲》(1)《動詞に伴って》『…に対して』,に,へ / (2)《形容詞[句]・[代]名倍に伴って》『…に対して』 / 《程度・範囲》『…[に至る]まで』 / 《時間の終り》『…まで』(till) / 《to one's+『名』の形で》(…が)『…したことに[は]』 / 《比較・対比・割合》『…と比べて』,より,に対して / 《一致・適合》『…に合わせて』,に合って,に応じて / 《目的・意図》『…のために』 / 《運命・境遇》『…に』 / 《所属・関係》『…へ』,に[対して] / 《付加・付着・固執》『…に』 / 《対立・対向》…に[対して] / いつもの状態(位置)に / 停止(閉鎖)の状態に / 活動状態に(へ),仕事に
《名詞的用法》『…すること』 / 《形容詞的用法》『…するための,すべき』 / 《副詞的用法》『…するために』,して,するとは,すれば / 《独立用法》 / 《文全体を修飾する慣用語句》…すれば,してみると,…だが / 短縮文
…‘を'チリンチリナ(リンリン)と鳴らす / チリンチリン鳴る宴
足指のある / 《複合語を作って》足指が…の:five-toed 足指が5本の

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 腫瘍壊死因子α（TNF-α）阻害剤：抗体、自己抗体、および自己免疫疾患の誘導 tumor necrosis factor alpha inhibitors induction of antibodies autoantibodies and autoimmune diseases
2. クローン病におけるインフリキシマブ infliximab in crohns disease
3. 腫瘍壊死因子α（TNF-α）阻害剤：副作用の概要 tumor necrosis factor alpha inhibitors an overview of adverse effects
4. 抗核抗体の測定および臨床的意義 measurement and clinical significance of antinuclear antibodies
5. 成人における重症または難治性クローン病の内科的マネージメントの概要 overview of the medical management of severe or refractory crohns disease in adults

English Journal

Induced production of anti-etanercept antibody in collagen-induced arthritis.

Yi H, Kim J, Jung H, Rim YA, Kim Y, Jung SM, Park SH, Ju JH.Author information Division of Rheumatology, Department of Internal Medicine, CiSTEM Laboratory, Convergent Research Consortium for Immunological Disease (CRCID), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea.AbstractEtanercept is a widespread biological drug for the treatment of rheumatoid arthritis, which inhibits tumor necrosis factor-α (TNF-α). Recently, the presence of antibodies targeting TNF-α inhibitors such as infliximab and adalimumab, was reported. However, few reports have studied etanercept in a mouse model of arthritis. We investigated the induction of anti-etanercept antibody production, along with the antibody's potential interfering effects on the biological function of etanercept, in mice with collagen-induced arthritis (CIA). CIA mice received an intraperitoneal injection of etanercept (25, 100 or 400 µg per mouse). The degree of inflammation and cartilage erosion was evaluated, and the number of osteoclasts in the ankle joints was assessed by TRAP staining. The level of pro-inflammatory cytokines in the serum was measured. To analyze the anti-osteoporotic effect of etanercept, microfocal computed tomography analyses of femurs and tibias were performed. Etanercept treatment decreased both the incidence and severity of arthritis in a dose-dependent manner, except for the highest dose of 400 µg. The mice that were treated with 25 and 100 µg etanercept showed an improvement in inflammation, cartilage damage, and even bone loss. However, mice treated with 400 µg etanercept showed no significant improvement in any of the tested parameters. Using a customized enzyme-linked immunosorbent assay (ELISA), the presence of the anti-etanercept antibody was detected in the serum in this treatment-refractory group. The therapeutic effect of etanercept was reduced in the CIA mice that developed the anti-etanercept antibody. In conclusion, the production of an anti-etanercept antibody can be induced in CIA mice, and this antibody can considerably reduce the anti-arthritic and anti‑osteoporotic effects of etanercept.
Molecular medicine reports.Mol Med Rep.2014 Jun;9(6):2301-8. doi: 10.3892/mmr.2014.2127. Epub 2014 Apr 9.
Etanercept is a widespread biological drug for the treatment of rheumatoid arthritis, which inhibits tumor necrosis factor-α (TNF-α). Recently, the presence of antibodies targeting TNF-α inhibitors such as infliximab and adalimumab, was reported. However, few reports have studied etanercept in a
PMID 24718553

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.

Levesque BG1, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG.Author information 1Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.AbstractBACKGROUND: Patients with Crohn's disease (CD) may experience disease relapse on maintenance infliximab. Anti-drug antibodies likely contribute to loss of response, and serum infliximab levels likely correlate with efficacy.
Alimentary pharmacology & therapeutics.Aliment Pharmacol Ther.2014 May;39(10):1126-35. doi: 10.1111/apt.12733. Epub 2014 Apr 1.
BACKGROUND: Patients with Crohn's disease (CD) may experience disease relapse on maintenance infliximab. Anti-drug antibodies likely contribute to loss of response, and serum infliximab levels likely correlate with efficacy.AIM: To prospectively evaluate the relationship between trough serum inflixi
PMID 24689499

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

Osterman MT1, Haynes K2, Delzell E3, Zhang J3, Bewtra M4, Brensinger C5, Chen L6, Xie F6, Curtis JR7, Lewis JD8.Author information 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.2Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Teaching, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.3Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama.4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.5Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.6Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama.7Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Teaching, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: lewisjd@mail.med.upenn.edu.AbstractBACKGROUND & AIMS: Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2014 May;12(5):811-817.e3. doi: 10.1016/j.cgh.2013.06.010. Epub 2013 Jun 28.
BACKGROUND & AIMS: Antibodies against tumor necrosis factor-α are widely used to treat patients with Crohn's disease (CD). This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD.METHODS: We conducted a
PMID 23811254

Japanese Journal

Infliximab二次無効クローン病における関連因子 (特集炎症性腸疾患の病態解明と治療戦略)

曽野浩治,山田哲弘,吉松安嗣 [他]
消化器内科 57(5), 568-574, 2013-11
NAID 40019896066

Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn's disease after anti-tumor necrosis factor-α therapy

, , , , , , , ,
Journal of Clinical Biochemistry and Nutrition 53(2), 122-127, 2013
… We investigated the effects of treatment with antibodies against tumor necrosis factor (TNF)-α on energy metabolism, nutritional status, serum cytokine levels in patients with Crohn's disease (CD). … Serum interleukin-6 levels were significantly decreased and RQ were significantly increased in high REE (≥25 kcal/kg/day) group as compared to low REE (<25 kcal/kg/day) group. …
NAID 130004466718

粘膜治癒・長期予後の面からみた難治性炎症性腸疾患の治療戦略

長沼誠,藤井俊光,渡辺守
日本臨床免疫学会会誌 = Japanese journal of clinical immunology 35(2), 99-106, 2012-04-28
潰瘍性大腸炎とクローン病は原因不明であり再燃と寛解を繰り返す難治性炎症性腸疾患である．従来5-アミノサリチル酸製剤，栄養療法，副腎皮質ステロイド剤，チオプリン製剤（アザチオプリン）が治療の中心であったが，近年新しい免疫抑制剤であるタクロリムスや抗TNFa抗体製剤であるインフリキシマブやアダリムマブが開発され，臨床の現場で使用可能となっている．最近では作用機序の弱い薬剤から強い薬剤へステップアッ …
NAID 10030573724